SCHEMBL6091141

SCHEMBL6091141

O=C(C=CC12CC3CC(CC(C3)C1)C2)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.49
EPHX1 P07099 1/20 0.47
P2RX7 Q99572 3/20 0.45
ALDH1A1 P00352 5/20 0.45
LMNA P02545 3/20 0.45
MAPT P10636 3/20 0.45
NPSR1 Q6W5P4 3/20 0.45
PLIN1 O60240 2/20 0.45
PLIN5 Q00G26 2/20 0.45
ABHD5 Q8WTS1 2/20 0.45
HTT P42858 2/20 0.45
HPGD P15428 1/20 0.45
RECQL P46063 2/20 0.44
MAOB P27338 2/20 0.44
BCHE P06276 1/20 0.44
TNFRSF1A P19438 1/20 0.44
ACHE P22303 1/20 0.44
CYP1B1 Q16678 1/20 0.44
KDM4E B2RXH2 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090897 0.84 P2RX7 (0.46) P2RX7ALDH1A1LMNAMAPTNPSR1
SCHEMBL18317449 0.84 RAB9A (0.45) P2RX7ALDH1A1LMNAMAPTRECQL
SCHEMBL6092329 0.84 KMT2A (0.48) EPHX1P2RX7ALDH1A1LMNAHTT
SCHEMBL6092092 0.84 TNFRSF1A (0.47) P2RX7ALDH1A1MAPTNPSR1HTT
SCHEMBL1769995 0.82 TSHR (0.56) P2RX7ALDH1A1LMNAMAPTNPSR1
SCHEMBL4728169 0.82 TSHR (0.56) P2RX7ALDH1A1LMNAMAPTNPSR1
SCHEMBL6091478 0.82 FAAH (0.61) FAAHMAOBEPHX2
SCHEMBL4731777 0.80 RAB9A (0.51) P2RX7ALDH1A1LMNAMAPTPLIN1
SCHEMBL6093069 0.80 ALDH1A1 (0.43) ALDH1A1LMNAMAPTNPSR1HTT
SCHEMBL6093038 0.80 HDAC1 (0.41) P2RX7ALDH1A1LMNAMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders MERZ PHARMA GMBH & CO. KGAA (DE) 2006-04-06 US claimed
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders MERZ PHARMA GMBH & CO. KGAA (DE) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders PMP22, ADCYAP1R1, CYP11B2 FAAH 459/4885EPHX1 1335/4885P2RX7 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.